Table 2

Warfarin patients switching to DOACs or remaining on warfarin

Patient count, thousands (percentage)
PeriodMarch–MayJune–August
Year2020201920202019
Baseline warfarin patients**164 000195 000143 200185 900
Switched20 000 (12.2)6900 (3.5)6300 (4.4)5900 (3.2)
Continued warfarin136 100 (83.0)177 300 (90.9)128 200 (89.5)169 900 (91.4)
No anticoagulants†7900 (4.8)10 800 (5.6)8700 (6.1)10 100 (5.4)
Switched back
(% of switchers)
1200 (5.8)300 (4.1)300 (4.7)300 (4.4)
At least one INR
(% of continued)
109 100 (80.1)148 400 (83.7)101 100 (78.8)140 000 (82.4)
At least one TTR
(% of continued)
52 600 (38.6)67 200 (37.9)50 300 (39.2)66 500 (39.1)
High INR (≥8)
(% of continued)
700 (0.5)700 (0.4)400 (0.3)600 (0.3)
  • Number and percentage of warfarin patients who continued on warfarin, received a DOAC (‘switched’) or had no anticoagulants, during March–May 2020 compared with 2019 and similarly for June–August. Also showing the percentage of those switching to a DOAC who later received warfarin ‘switched back’ (within the same 3-month period); and the percentage of those remaining on warfarin who had at least one INR test, INR TTR or high INR (≥8) recorded. Patient counts are rounded to the nearest 100.

  • *Baseline warfarin patients for each period were those issued warfarin at least once (but no DOACs) in the 3 months immediately prior to the period shown.

  • †Those with no anticoagulants (referring to warfarin and DOACs only) in the follow-up period may have discontinued anticoagulant treatment, moved to a non-TPP practice, died or simply had a long period without a new prescription from their GP (eg, due to a hospital stay or longer than usual prescription duration).

  • DOACs, direct-acting oral anticoagulants; INR, international normalised ratio; TTR, time in therapeutic range.